In contrast, patients with classic PNH, with active IVH, are eligible for complement inhibition, typically with terminal C5 inhibitors (C5i) such as eculizumab, ravulizumab, or crovalimab, or alternatively with pegcetacoplan, a proximal C3 inhibitor (C3i). The gene discussed is C3; the disease is paroxysmal nocturnal hemoglobinuria.